Expertise in

conditions

Dr. Margaret E. Macy

Pediatric Hematology Oncology

13123 E 16th Ave,

Aurora, CO

Clinical Trials:Currently Recruiting for 1 Trial

Expertise in

conditions

13123 E 16th Ave,

Aurora, CO

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Margaret Macy is a Pediatric Hematologist Oncology provider in Aurora, Colorado. Dr. Macy is highly rated in 17 conditions, according to our data. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Ewing Sarcoma, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 58 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in CO

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Humana

HMO
INDEMNITY
POS
PPO

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

UnitedHealthcare

Locations

13123 E 16th Ave, Aurora, CO 80045

Call: 720-777-1234

Additional Areas of Focus

Dr. Macy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

52 Clinical Trials

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

Enrollment Status: Recruiting

Publish Date: February 14, 2025

Intervention Type: Drug

Study Drug: Oral Repotrectinib (TPX-0005)

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Drug

Study Drug: Entrectinib

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Other

Study Drugs: Cabozantinib, Cabozantinib-S-Malate

Study Phase: Phase 2

3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers

Enrollment Status: Withdrawn

Publish Date: September 10, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 1

A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Other, Drug, Biological

Study Drugs: Dinutuximab, Isotretinoin, Lenalidomide

Study Phase: Phase 1

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: August 08, 2025

Intervention Type: Drug

Study Drug: Elimusertib

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: July 23, 2025

Intervention Type: Drug

Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide

Study Phase: Phase 1

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Enrollment Status: Active_not_recruiting

Publish Date: July 20, 2025

Intervention Type: Drug

Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine

Study Phase: Phase 1/Phase 2

A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma

Enrollment Status: Suspended

Publish Date: July 18, 2025

Intervention Type: Biological, Procedure

Study Drug: Trastuzumab Deruxtecan

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Enrollment Status: Active_not_recruiting

Publish Date: June 11, 2025

Intervention Type: Drug

Study Drug: Larotrectinib Sulfate

Study Phase: Phase 2

Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma

Enrollment Status: Completed

Publish Date: May 06, 2025

Intervention Type: Procedure, Biological

Study Phase: Phase 1

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: April 23, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 1/Phase 2

A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Enrollment Status: Completed

Publish Date: April 13, 2025

Intervention Type: Drug

Study Drugs: Azacitidine, Cytarabine, Fludarabine Phosphate, Methotrexate, Pevonedistat, Hydrocortisone

Study Phase: Phase 1

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: April 09, 2025

Intervention Type: Drug, Biological

Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide

Study Phase: Phase 2

A Phase 1 Study of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Enrollment Status: Completed

Publish Date: March 21, 2025

Intervention Type: Drug

Study Drugs: Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone

Study Phase: Phase 1

A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Enrollment Status: Terminated

Publish Date: February 12, 2025

Intervention Type: Drug

Study Drug: TK216

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Enrollment Status: Completed

Publish Date: January 14, 2025

Intervention Type: Drug, Other

Study Drug: Selinexor

Study Phase: Phase 1

A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan

Enrollment Status: Completed

Publish Date: January 14, 2025

Intervention Type: Drug, Other

Study Phase: Phase 1

A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Enrollment Status: Active_not_recruiting

Publish Date: January 09, 2025

Intervention Type: Drug, Biological

Study Drugs: Cytarabine, Flotetuzumab

Study Phase: Phase 1

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

Enrollment Status: Completed

Publish Date: December 11, 2024

Intervention Type: Drug

Study Drug: Olaparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

Enrollment Status: Completed

Publish Date: November 01, 2024

Intervention Type: Other, Drug

Study Drug: Palbociclib

Study Phase: Phase 2

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: October 22, 2024

Intervention Type: Drug

Study Drugs: Irinotecan, Pevonedistat, Temozolomide

Study Phase: Phase 1

A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: October 22, 2024

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Dinutuximab, Irinotecan, Isotretinoin, Sargramostim, Temozolomide

Study Phase: Phase 2

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Enrollment Status: Completed

Publish Date: October 03, 2024

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 1

A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors

Enrollment Status: Completed

Publish Date: July 15, 2024

Intervention Type: Biological, Other

Study Drug: Pepinemab

Study Phase: Phase 1/Phase 2

A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas

Enrollment Status: Completed

Publish Date: January 31, 2024

Intervention Type: Drug, Other, Radiation

Study Drug: Adavosertib

Study Phase: Phase 1

A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Enrollment Status: Completed

Publish Date: December 20, 2023

Intervention Type: Other, Drug

Study Phase: Phase 1

Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors

Enrollment Status: Completed

Publish Date: October 26, 2023

Intervention Type: Drug

Study Drug: Abemaciclib

Study Phase: Phase 1

A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Enrollment Status: Completed

Publish Date: October 17, 2023

Intervention Type: Drug, Other

Study Drug: Entinostat

Study Phase: Phase 1

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

Enrollment Status: Completed

Publish Date: October 17, 2023

Intervention Type: Biological, Other

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 1/Phase 2

A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: September 26, 2023

Intervention Type: Drug

Study Drugs: Adavosertib, Irinotecan Hydrochloride

Study Phase: Phase 1/Phase 2

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma

Enrollment Status: Terminated

Publish Date: September 13, 2023

Intervention Type: Drug

Study Drugs: Ramucirumab, Gemcitabine, Docetaxel

Study Phase: Phase 1/Phase 2

A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)

Enrollment Status: Completed

Publish Date: September 08, 2023

Intervention Type: Drug, Other, Biological

Study Drugs: Cytarabine, Filgrastim, Fludarabine, Liposomal Daunorubicin, Liposomal Cytarabine

Study Phase: Phase 1/Phase 2

An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma (Not Eligible for Approved Treatment)

Enrollment Status: Available

Publish Date: February 28, 2023

Intervention Type: Radiation

A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma

Enrollment Status: Completed

Publish Date: October 24, 2022

Intervention Type: Drug, Biological, Other

Study Drugs: Dinutuximab, Irinotecan Hydrochloride, Sargramostim, Temozolomide, Temsirolimus

Study Phase: Phase 2

A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: February 15, 2022

Intervention Type: Other, Drug

Study Phase: Phase 1

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

Enrollment Status: Terminated

Publish Date: May 19, 2021

Intervention Type: Drug

Study Phase: Not Applicable

A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies

Enrollment Status: Completed

Publish Date: March 26, 2021

Intervention Type: Other, Drug

Study Phase: Phase 1/Phase 2

View 49 Less Clinical Trials

45 Total Publications

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 23, 2025

View All 45 Publications

Similar Doctors

Expertise in

conditions

Dr. Marilyn J. Manco

Pediatric Hematology Oncology

Expertise in

conditions

Dr. Marilyn J. Manco

Pediatric Hematology Oncology

University Physicians Incorporated

13123 E 16th Ave,

Aurora, CO

(0.1 miles away)

720-777-1234

Languages Spoken:

English

See accepted insurances

Marilyn Manco is a Pediatric Hematologist Oncology provider in Aurora, Colorado. Dr. Manco is highly rated in 7 conditions, according to our data. Her top areas of expertise are Hemophilia A, Blood Clots, Mesenteric Venous Thrombosis, Hemophilia B, and Thrombectomy.

Expertise in

conditions

Dr. Nicholas K. Foreman

Pediatric Hematology Oncology

Expertise in

conditions

Dr. Nicholas K. Foreman

Pediatric Hematology Oncology

University Physicians Incorporated

13123 E 16th Ave,

Aurora, CO

(0.1 miles away)

720-777-1234

Languages Spoken:

English

See accepted insurances

Nicholas Foreman is a Pediatric Hematologist Oncology provider in Aurora, Colorado. Dr. Foreman is highly rated in 10 conditions, according to our data. His top areas of expertise are Medulloblastoma, Ganglioglioma, Glioma, and Rhabdoid Tumor.

Expertise in

conditions

Dr. Rajeev Vibhakar

Pediatric Hematology Oncology

Expertise in

conditions

Dr. Rajeev Vibhakar

Pediatric Hematology Oncology

13123 E 16th Ave,

Aurora, CO

(0.1 miles away)

720-777-1234

Languages Spoken:

English

See accepted insurances

Rajeev Vibhakar is a Pediatric Hematologist Oncology provider in Aurora, Colorado. Dr. Vibhakar is highly rated in 9 conditions, according to our data. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Rhabdoid Tumor.

VIEW MORE Pediatric Hematologist Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Macy's expertise for a condition

ConditionClose